REVIEW QUESTION/OBJECTIVE The aim of this review is to assess the best available evidence regarding risk factors for discontinuation from anti-retroviral therapy in Ethiopia. Specifically, the review will be assessing the association between discontinuation from anti-retroviral therapy and the following: • Socio-demographic and economic factors • Behavioral factors • Clinical factors • Institutional factors.
Since its emergency in the 1980s, the human immunodeficiency virus (HIV) has been infected people of all ages, sexes, races and income status, leading to poor health and socio-economic outcomes across the world.1 Since its epidemic recognition, almost 78 million people have been infected and about half of these people have died of its sequel, AIDS.2 By the end of 2013, globally, 35 million (33.2–37.2 million) people were living with HIV, of whom nearly 0.8% were adults aged 15–49 years.2
Africa, Asia and Latin America were the major continents affected by the disease. A total of 24.7 million people were infected with HIV whereby Sub-Saharan Africa was the hardest hit subcontinent. The subcontinent was home for nearly 71% of people infected with HIV, and one in every 20 adults was living with the virus. At the end of 2013, in Ethiopia, the prevalence of HIV was 1.2% with approximately 0.8 million people living with the virus. Given that there is currently no cure and any human being is susceptible to this scourge, the advent of its treatment, anti-retroviral therapy, known to prolong the life of HIV patients, was a significant achievement.
|Number of pages||12|
|Journal||JBI Database of Systematic Reviews and Implementation Reports|
|Publication status||Published - 1 Feb 2016|
- Lost to follow up